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Introduction
Rhabdomyosarcoma (RMS) is a heterogeneous family of tumors 
sharing features with the skeletal muscle lineage. It is the most 
common soft tissue sarcoma in childhood and can be classified into 
2 main histological subtypes, alveolar RMS (aRMS) and embryonal 
RMS (eRMS). These are not only histologically distinguishable but 
also associated with distinct clinical and molecular profiles. aRMS 
is the more aggressive form of RMS, with a higher rate of metasta-
sis and a poorer prognosis. Current treatment modalities, including 
chemotherapy, surgery, and radiation, have steadily improved sur-
vival of RMS patients, but, especially for aRMS patients with meta-
static disease, survival rates remain dismal (1, 2). So far there are no 
targeted therapies available that could improve overall cure rates 
and reduce long-term sequelae. About 80% of aRMSs are charac-
terized by a specific chromosomal translocation generating PAX3-
FOXO1 or PAX7-FOXO1 fusion transcription factors (fusion-posi-
tive RMS [FP-RMS]) (3). It is now well accepted that fusion status 
drives unfavorable outcome in patients with RMS, especially for 
the PAX3-FOXO1 fusion (4–7). Therefore fusion status has become 
a very important prognostic marker in the clinics. The fusion 
proteins are characterized by aberrant expression levels, greater 
posttranslational stability, exclusive nuclear localization, and a 
more potent transcriptional function compared with WT PAX3/
PAX7 (8–11). Furthermore, numerous studies have highlighted the 
oncogenic ability of the PAX3-FOXO1 fusion protein and its funda-
mental contribution toward FP-RMS tumorigenesis (12–17). Since 
FP-RMS cells are addicted to the oncogenic capacity of PAX3-
FOXO1 expression, it remains a very attractive therapeutic target 
(18–21). However, direct targeting of transcription factors persists 
in being challenging. Therefore, many studies have been conduct-
ed to identify PAX3-FOXO1 downstream targets or cooperating 
mutations that are potentially required for oncogenic transforma-
tion (reviewed in ref. 22). Many putative therapeutically relevant 
signaling pathways have been described with varying degrees of 
tumor cells’ dependence on them and therefore also varying tumor 
response upon inhibition. Also, their complexity, crosstalk, and 
acquired drug resistance often limit clinical application of drugs 
targeting key components of these pathways (23–25). Furthermore, 
pediatric cancers in general are known to carry very few mutations 
compared with adult tumors, and recent comprehensive genomic 
analysis has identified a particularly low overall mutational burden 
in FP-RMS, decreasing the number of potential actionable targets 
and underscoring the importance of the fusion proteins as domi-
nant driver (26, 27).
Epigenetic regulation is an emerging field in cancer biolo-
gy and provides novel therapeutic possibilities (28). Several his-
tone demethylases and histone methyltransferases are highly 
expressed in FP-RMS and have been shown to maintain the undif-
ferentiated phenotype of tumor cells or promote their survival. 
In these known cases, epigenetic modulators act as either direct 
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ity and serve as rational therapeutic targets, we designed a 2-step 
screening approach (Figure 1A). First, we performed mass spec-
trometry (MS) analysis of proteins that interact with PAX3-FOXO1. 
FP-RMS cells RH4 and RMS13 were transiently transfected with 
triple FLAG-tagged PAX3-FOXO1 or, as control, FLAG only expres-
sion vectors. Using both N- and C-terminally FLAG-tagged PAX3-
FOXO1 prevented loss of interactors due to interference with the 
localization of the tag. Additionally, we combined high-level CMV 
promoter–driven PAX3-FOXO1 expression for maximum protein 
recovery with low-level long terminal repeat promoter–driven 
PAX3-FOXO1 expression, minimizing nonspecific interactions 
(Supplemental Figure 1A; supplemental material available online 
with this article; doi:10.1172/JCI85057DS1). We analyzed 4 inde-
pendent FLAG-affinity purifications of PAX3-FOXO1 together 
with controls (Figure 1B) by MS, which confirmed the presence of 
PAX3-FOXO1 with a minimum coverage of 54% in each replicate 
experiment including PAX3-FOXO1 breakpoint-specific peptides 
(Supplemental Figure 1B). Considering only proteins found with a 
or indirect target genes downstream of PAX3-FOXO1 (29–32). 
In contrast, epigenetic mechanisms that would orchestrate the 
network of aberrant transcriptional activity at the level of PAX3-
FOXO1 itself are largely unknown.
Here, we used a 2-step screening approach to identify novel 
PAX3-FOXO1 coregulators that might be essential for its aberrant 
transcriptional activity. We identified chromodomain helicase 
DNA binding protein 4 (CHD4) as crucial coregulator of PAX3-
FOXO1 activity that co-occupies a subset of PAX3-FOXO1 binding 
regions. Our results suggest that CHD4 represents a novel onco-
genic epigenetic chromatin remodeler required to orchestrate a 
subsignature of PAX3-FOXO1 target genes and thereby maintain 
tumor cell survival.
Results
A 2-step screening approach identifies several NuRD complex compo-
nents as PAX3-FOXO1 coregulators. To identify PAX3-FOXO1–inter-
acting proteins in FP-RMS that may contribute to its aberrant activ-
Figure 1. Two-step proteomic and siRNA screen identifies putative PAX3-FOXO1 interaction partners. (A) Schematic representation of the 2-step screen-
ing approach. (B) Representative silver-stained gel of FLAG immunoprecipitates from RMS13 cells transfected with FLAG-tagged PAX3-FOXO1. The aster-
isk marks the band corresponding to FLAG-PAX3-FOXO1. RMS13 cells expressing only FLAG-tag served as negative control. (C) SiRNA screening results 
for 60 candidate interactors. Each candidate was silenced using 3 different siRNAs per target. Fold change of expression of PAX3-FOXO1 target genes was 
measured by quantitative real-time PCR relative to RH4 cells treated with scrambled control. Values for the 9 candidate interactors resulting from the 
siRNA screen are indicated. (D) Schematic representation of the NuRD complex. General subunit composition and components with enzymatic activity are 
displayed. NuRD subunits identified by MS are marked in red.
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classes of genes affected by PAX3-FOXO1, including those activat-
ed from enhancer sites (NMYC), from intronic sites or promoters 
(PIPOX and CDH3 ), or via unknown mechanisms (TFAP2B), as 
well as 1 repressed gene (MYL1) (19, 34–37). For each siRNA, fold 
change of target gene expression relative to scrambled control was 
determined by quantitative real-time PCR. We considered a fold 
change below 0.75 for activated and above 1.25 for repressed target 
genes as threshold to narrow down the list of candidates (Figure 
1C). Considering, in addition, candidates affecting at least 2 target 
genes by at least 2 independent siRNAs, we identified 9 interactors 
that might potentially modulate PAX3-FOXO1 activity (Figure 1C 
and Supplemental Figure 2). Each of the 9 candidate interactors 
affected expression of only a subset of the target genes measured, 
reflecting potentially diverse mechanisms by which the fusion pro-
tein regulates target gene expression. 
minimum of 2 unique peptides in at least 2 replicate experiments 
and none of the controls, we identified 230 putative PAX3-FOXO1 
candidate interactors (Supplemental Table 1). 
To narrow down the list to candidate interactors that potential-
ly would affect PAX3-FOXO1 transcriptional activity, we applied 
a subsequent siRNA screen (Figure 1A) targeting 60 preselected 
candidate interactors (Supplemental Table 2). Preselection was 
based on number of unique peptides identified by MS combined 
with possible function as described in the literature. Additionally, 
we used gene expression data from different FP-RMSs to include 
only candidates with detectable expression levels (24). RH4 cells, 
whose gene expression signature represents most closely tumor 
biopsies (19, 33), were individually transfected with 3 unique siRNA 
sequences per target and transcript levels of 5 PAX3-FOXO1 target 
genes measured after 48 hours. These genes represent different 
Figure 2. Silencing of CHD4 affects specifically FP-RMS cell expansion. (A) Left panels: Western blots after knockdown of CHD4 or LSD1 in RH4 cell 
extracts 72 hours after induction with doxycycline (Dox.). Uninduced cells served as negative control, and actin or tubulin was used as loading control. 
Right panels: RH4 cell expansion was measured by WST assay at indicated time points after silencing of LSD1 or CHD4 by shRNA induction with doxycy-
cline. Data represent the mean ± SD of 3 independent experiments and were normalized to uninduced cells. PAX3-FOXO1 knockdown served as positive 
control. (B) Western blots and cell expansion after LSD1 or CHD4 knockdown in RD cells treated and analyzed as in A. (C) Western blots and cell prolifera-
tion after CHD4 knockdown in human myoblast or MRC5 cells treated and analyzed as in A.
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In conclusion, our 2-step screening approach identified sev-
eral chromatin remodeling proteins and complexes as potentially 
interacting directly or indirectly with PAX3-FOXO1, and points 
particularly to a specific role of the NuRD complex in regulating 
PAX3-FOXO1 target genes.
CHD4 is crucial for FP-RMS cell expansion in vitro. To fur-
ther study the biological role of the NuRD complex, we select-
ed CHD4 and LSD1 as members of the complex, which have 
not been studied in RMS and possess a potentially druggable 
enzymatic activity, and assessed whether their silencing would 
affect FP-RMS cell expansion. We established an inducible len-
tiviral expression system of stable cell lines expressing LSD1- or 
CHD4-specific shRNAs upon doxycycline treatment. Silenc-
ing was validated on mRNA and protein expression levels 72 
hours after induction of shRNA expression with 2 independent 
Remarkably, 5 of the 9 candidates represent components of 
chromatin remodeling complexes. CHD4, lysine-specific demeth-
ylase 1 (LSD1), and retinoblastoma binding protein 4 (RBBP4) 
are components of the nucleosome remodeling and deacetylase 
(NuRD) complex (38, 39), whereas REST corepressor 1 (RCOR1) 
and LSD1 can also be subunits of the CoREST complex (40, 41). 
In addition, the atypical tyrosine protein kinase BAZ1B is a bromo-
domain-containing protein found in different chromatin remod-
eling complexes (42). Importantly, our MS experiments identified 
several subunits of the NuRD complex, namely RBBP7 and his-
tone deacetylases 1 and 2 (HDAC1 and HDAC2), which can func-
tion in diverse chromatin-regulating complexes, as well as GATA 
zinc finger–containing protein 2A (GATAD2A) and metastasis-as-
sociated protein 2 (MTA2), which are more specific components of 
the NuRD complex (Figure 1D and Supplemental Table 1).
Figure 3. CHD4 knockdown decreases viability of FP-RMS cells. (A) Caspase-3/7 activity was measured in RH4 cells 72 hours after induction of CHD4 
silencing. Fold change of caspase-3/7 activity was normalized to uninduced cells. Shscr-treated cells served as negative and PAX3-FOXO1 knockdown 
cells as positive controls. Values represent the mean ± SD of 3 independent biological experiments. (B) Percentage of dead cells 96 hours after induction 
of CHD4 silencing. Cells were stained with NucView Caspase-3 Substrate and 7AAD and analyzed by flow cytometry. Values represent the mean ± SD of 4 
independent experiments (**P < 0.01; ***P < 0.001; uncorrected Fisher’s LSD). (C) Western blot of PARP and cleaved caspase-7 from extracts of RH4 cells 
72 hours after induction of CHD4 or PAX3-FOXO1 silencing and uninduced or shscr-treated control cells. (D) Representative phase-contrast images of RH4 
cells 72 hours after induction of silencing with doxycycline (Dox.) transduced with indicated constructs; original magnification, ×100. (E) Clonogenic assays 
of RH4 cells 12 days after induction of CHD4 silencing. Quantitation of number of colonies with black lines representing the mean values. Representative 
images of crystal violet–stained colonies are shown in the right panel.
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CHD4 but not LSD1 function is essential for expansion specif-
ically of translocation-driven FP-RMS cells, whereas it does 
not affect the growth of normal cells. Based on this result, we 
focused our studies on CHD4.
CHD4 promotes FP-RMS cell survival. Next, we asked wheth-
er reduction in cell numbers upon CHD4 depletion was due to 
loss of viability. To this end, we measured caspase-3/7 activity 
after induction of CHD4 silencing in 2 FP-RMS cell lines (RH4 
and RMS) over a period of 3 days (Figure 3A and Supplemental 
Figure 4A). Both CHD4-specific shRNAs increased caspase-3/7 
activity between 3- and 6-fold in RH4 cells and to a lesser extent 
in the FP-RMS cell line RMS relative to control. Increased 
caspase-3/7 activity after CHD4 knockdown was additionally 
confirmed in both cell lines by detection of active caspase-3/7 in 
individual cells by flow cytometry (Supplemental Figure 5). Fur-
thermore, we quantified the percentage of dead cells 96 hours 
after induction of CHD4 silencing by combined detection of 
sequences per target in 2 different FP-RMS cell lines (RH4 and 
RMS) (Figure 2A and Supplemental Figure 3, A and B). As posi-
tive control we used a shRNA sequence based on a recently pub-
lished PAX3-FOXO1 breakpoint-specific siRNA (siPF2) (ref. 18 
and Supplemental Figure 3, A and B). Cell expansion was mea-
sured over 4 days and normalized to control cells to exclude dox-
ycycline-mediated effects (43). We found that LSD1 depletion 
had only minor effects on RH4 expansion. In contrast, CHD4 
knockdown decreased cell numbers of both cell lines to less than 
30% of control, comparable to depletion of the fusion protein 
itself (Figure 2A and Supplemental Figure 3C). To assess spec-
ificity for FP-RMS, we performed the same experiments in the 
fusion-negative RMS (FN-RMS) cell line RD and did not observe 
any influence of CHD4 depletion on cell numbers (Figure 2B). 
Importantly, neither nontransformed human fibroblasts nor 
normal primary myoblast cells were affected by CHD4 deple-
tion (Figure 2C). Taken together these results demonstrate that 
Figure 4. CHD4 and PAX3-FOXO1 mainly interact via short DNA fragments. (A) Representative Western blots of endogenous PAX3-FOXO1 immunopre-
cipitates and lysates from 3 different FP-RMS cell lines. PAX3-FOXO1 was immunoprecipitated by the anti-FOXO1 antibody, and uncoated beads served as 
negative control (ctrl). (B) Representative Western blot of reciprocal CHD4 immunoprecipitate from RH4 cells. Endogenous CHD4 was immunoprecipitated 
by an anti-CHD4 antibody, and uncoated beads served as negative control (ctrl). (C) Western blot detection of indicated proteins in anti-FLAG immu-
noprecipitates and lysates from 293T cells transfected with FLAG-tagged P3F and Myc-tagged CHD4. Cell lysate was treated with indicated amounts of 
Benzonase during immunoprecipitation to digest the DNA, and DNA digestion was evaluated by agarose gel electrophoresis. (D) Western blot detection of 
indicated endogenous proteins in anti-FOXO1 immunoprecipitates from RH4 cells. Uncoated beads served as negative control (ctrl). Lysates were digested 
or not with 250 U/ml Benzonase, and DNA digestion was evaluated by agarose gel electrophoresis. (E) Western blot detection of indicated endogenous 
proteins in anti-FLAG immunoprecipitates from RH4 cells with stable knock-in of 3X FLAG at C-terminus of CHD4. Uncoated beads served as negative 
control (Ctrl). Lysates were digested or not with 250 U/ml Benzonase, and DNA digestion was evaluated by agarose gel electrophoresis.
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active caspase-3/7–positive and 7-aminoactinomycin D–posi-
tive (7-AAD–positive) cells (Figure 3B, Supplemental Figure 4B, 
and Supplemental Figure 6). This revealed that CHD4 depletion 
increased the percentage of dead cells from 22% to 48% in RH4 
(21% to 51% in the cell line RMS), a level similar to that seen 
with depletion of PAX3-FOXO1 (increase from 20% to 43% in 
RH4, 21% to 47% in the cell line RMS), whereas caspase-3/7 was 
active in the majority of dying cells. In addition, protein anal-
ysis of CHD4-depleted cells demonstrated increased levels of 
cleaved caspase-7 and cleaved PARP in FP-RMS cells (Figure 
3C and Supplemental Figure 4C), which were not detected in 
normal human fibroblasts or myoblasts (data not shown). These 
markers of apoptotic cell death also correlated with an increased 
number of floating cells, observed only in FP-RMS cells but not 
in normal human fibroblasts or myoblasts (Figure 3D, Supple-
mental Figure 4D, and Supplemental Figure 7). Finally, CHD4 
depletion impaired the ability of both FP-RMS cell lines to form 
colonies in clonogenic cell survival assays (Figure 3E and Sup-
plemental Figure 4E). In summary, the data demonstrate that 
the antiproliferative effect of CHD4 depletion in FP-RMS cells 
is due to increased cell death, suggesting that CHD4 expression 
is necessary to promote tumor cell survival.
CHD4 interacts with PAX3-FOXO1 via short DNA fragments. 
To get mechanistic insights into the interaction of PAX3-FOXO1 
with NuRD complex members, we first immunoprecipitated 
endogenous PAX3-FOXO1 from 3 different FP-RMS cell lines 
(RH4, RMS13, and RMS) with an anti-FOXO1 antibody and 
found specific coprecipitation of HDAC1, HDAC2, LSD1, and 
CHD4, but not with the negative control (Figure 4A). Impor-
tantly, these interactions persisted also after silencing of WT 
FOXO1 with a FOXO1-specific siRNA (Supplemental Figure 8), 
indicating that they do not depend on WT FOXO1, which can 
also be immunoprecipitated by the anti-FOXO1 antibody. In 
support, immunoprecipitation of CHD4 was able to pull down 
PAX3-FOXO1 (Figure 4B) in the reciprocal approach. To fur-
ther investigate whether interaction of CHD4 and PAX3-FOXO1 
occurs by direct protein-protein contact, we expressed tagged 
proteins together in HEK293T cells and immunoprecipitated 
FLAG-PAX3-FOXO1. Interestingly, under normal conditions 
we observed efficient pull-down of CHD4, whereas digestion of 
DNA with increasing amounts of Benzonase gradually decreased 
coprecipitated CHD4 (Figure 4C). Similar observations were 
made with the endogenous proteins CHD4 and HDAC2 in 
FP-RMS cells (Figure 4D), whereas the previously characterized 
Figure 5. CHD4 coregulates PAX3-FOXO1–activated target genes. (A) Heat map of unsupervised hierarchical clustering of PAX3-FOXO1 (siP3F) and CHD4 
(shCHD4#1) knockdown profiles using the gene set directly regulated by PAX3-FOXO1 (638 genes differently expressed between siP3F-treated and sis-
cr-treated [24 and 48 hours after transfection] or untreated RH4 cells; fold change >1.5; P < 0.05). Each column represents a different time point for shR-
NA-treated cells in singlicate and for siRNA-treated cells in duplicate (24, 48, 72 hours from left to right for each condition). Numbers of coexpressed genes 
between these transcriptional profiles are displayed. (B) Schematic representation of genes directly regulated by PAX3-FOXO1 and CHD4 (fold change 
>1.5; P < 0.05 between siP3F-treated and siscr-treated [24 and 48 hours after transfection] or untreated RH4 cells and between shCHD4-expressing and 
shscr-expressing RH4 cells [24 and 48 hours after doxycycline induction] or uninduced control cells). The coregulated subset as read out from the heatmap 
clustering in A is displayed. (C) GSEA using CHD4-regulated genes in RH4 cells as the rank-ordered data set and targets directly upregulated by PAX3-
FOXO1 as the gene set (259 genes differently expressed between siP3F-treated and siscr-treated or untreated RH4 cells 24 and 48 hours after transfection; 
fold change >1.7; P < 0.05). Normalized enrichment score (NES) and P value are shown.
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interaction between the NuRD components CHD4 and HDAC2 
was unaffected by Benzonase treatment (Figure 4E). The data 
suggest that the interaction between PAX3-FOXO1 and CHD4 is 
mainly dependent on short DNA fragments to which the 2 factors 
bind in close proximity.
CHD4 depletion affects PAX3-FOXO1–activated target genes. 
Given the importance of CHD4 for FP-RMS cell survival and the 
observation that none of the initial candidates, including CHD4, 
affected all 5 PAX3-FOXO1 target genes in our primary siRNA 
screen, we sought to explore the global effects of CHD4 depletion 
on the PAX3-FOXO1 transcriptome. Therefore, we performed gene 
expression profiling on RNA isolated from RH4 cells 24, 48, and 72 
hours after CHD4 depletion. We analyzed gene expression chang-
es in regard to a recently published PAX3-FOXO1 gene expression 
signature (19), since we hypothesized that predominantly direct 
PAX3-FOXO1 target genes might be affected, focusing on genes 
showing at least 1.5-fold up- or downregulation at the early time 
points (24 and 48 hours) after PAX3-FOXO1 silencing. Hierarchi-
cal clustering of this target gene signature revealed that the CHD4 
gene expression signature clusters together with the PAX3-FOXO1 
signature and not with the control-treated cells (Figure 5A). Com-
parison of both signatures affirms that CHD4 depletion affects 
only a subset of the PAX3-FOXO1 target gene signature and mainly 
overlaps in genes that are normally upregulated by PAX3-FOXO1. 
Indeed, the overlapping coregulated subset is composed of 257 
genes of a total of 638 genes affected by PAX3-FOXO1 depletion 
(Figure 5B). This further supports a model in which PAX3-FOXO1 
drives expression of target gene subsets in concert with different 
(epigenetic) mechanisms and indicates that CHD4 is important 
for a subset of PAX3-FOXO1–mediated transcriptionally activated 
target genes. Gene set enrichment analysis (GSEA) confirmed this 
conclusion by unraveling a significant correlation of CHD4 expres-
sion signature only with genes directly activated by PAX3-FOXO1, 
not with genes inhibited by PAX3-FOXO1 nor with genes showing 
changes only at later time points (Figure 5C and Supplemental Fig-
ure 9). The leading-edge subset of this coactivated gene set con-
sists of 47 genes (Supplemental Table 3). Besides the PAX3-FOXO1 
target genes already examined in our primary siRNA screen, we 
found that CHD4 inhibition had a strong impact on expression of 
anaplastic lymphoma kinase (ALK) and cannabinoid receptor 1 
(CB1), both PAX3-FOXO1 target genes that have been implicated 
in the tumor biology of FP-RMS (44, 45). In particular, expression 
of CB1 has been correlated with increased invasiveness of FP-RMS 
tumors (45). Therefore, our data suggest that CHD4 expression is 
required to coregulate a subset of PAX3-FOXO1 target genes that 
are necessary and sufficient to promote FP-RMS survival.
Figure 6. CHD4 colocalizes to PAX3-FOXO1 binding sites. (A) Expression levels of indicated PAX3-FOXO1 target genes were quantified by quantitative real-
time PCR after CHD4 knockdown in 2 FP-RMS cell lines. Bar charts are geometric means from 4 independent experiments with 95% CI (P < 0.05; Dunnett’s 
multiple comparison test). Fold change of mRNA expression was normalized to uninduced cells with PAX3-FOXO1 knockdown serving as positive control. 
(B) ChIP was performed in RH4 cells using PAX3/7 and CHD4 antibodies on known PAX3-FOXO1 DNA binding sites in target genes, and only beads without 
antibody served as negative control (Beads G). Bar charts indicate the mean ± SEM of at least 3 independent biological replicates. Abundance of precip-
itated DNA fragments was measured by quantitative PCR, and results are presented as the percentage of input. The GAPDH promoter region served as 
negative control. (C) Effect on PAX3-FOXO1 binding upon CHD4 silencing (48 hours of incubation with doxycycline) was determined by ChIP as described in 
B and is shown as fold enrichment over PAX3-FOXO1 ChIP signal in the presence of CHD4 (no doxycycline control).
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PAX3-FOXO1 in the GAPDH promoter region. This indicates that 
fusion protein binding is modulated by the presence of CHD4. 
Further, CHD4 and PAX3-FOXO1 co-occupy the same sites in 
PAX3-FOXO1 target genes, suggesting coregulation of target gene 
expression by both CHD4 and the fusion protein, at least for a sub-
set of target genes.
CHD4 inhibition causes tumor regression in mouse xenografts. 
Based on the observation that CHD4 inhibition reduces FP-RMS 
cell proliferation and survival in vitro, we aimed to assess wheth-
er CHD4 inhibition affects FP-RMS tumor growth in vivo using 
xenograft mouse models. Immunocompromised NOD/SCID 
mice were engrafted s.c. with RH4 cells, containing stably inte-
grated tet-inducible shCHD4#1 or shscr expression vectors. Mice 
with established tumors of varying size (170–400 mm3) were treat-
ed i.p. with either vehicle or doxycycline solution at a dose of 53.3 
mg/kg on 2 consecutive days. Additionally, starting from the first 
day of treatment, mice were fed with doxycycline-supplemented 
or control food. Strikingly, we observed regression of tumor size 
upon CHD4 depletion, even in tumors with a large starting volume 
of 380 mm3 (Figure 7A). Both immunohistochemical analyses of 
tumors and determination of mRNA levels showed strong reduc-
tion of CHD4 expression in all depleted tumors (Figure 7, B and 
C). The CHD4-depleted tumors also displayed high expression of 
the apoptotic marker cleaved caspase-3, similar to our previous in 
vitro findings (Figure 7C).
CHD4 and PAX3-FOXO1 colocalize at PAX3-FOXO1 target 
genes. To examine whether the fusion protein indeed binds to 
target genes together with CHD4, we first validated selected 
PAX3-FOXO1 target genes with a known role in FP-RMS pathol-
ogy, in 2 different FP-RMS cell lines (RH4 and RMS) 72 hours 
after induction of CHD4 depletion (Figure 6A) (22, 36, 44–46). 
We observed similar modulation of target gene levels by deplet-
ing CHD4 or PAX3-FOXO1. Next, we used ChIP on previously 
published PAX3-FOXO1 binding sites at selected target genes 
(34). It is of note that the sites of PAX3-FOXO1 binding are most-
ly enhancer regions (e.g., NMYC, FGFR4, PIPOX) and only rarely 
promoter regions (e.g., CDH3) promoter region). We analyzed the 
occupancy of CHD4 around PAX3-FOXO1 binding sites together 
with the GAPDH promoter region as negative control. We were 
able to measure ChIP PCR values that were low, but significantly 
above background. First, we confirmed PAX3-FOXO1 binding to 
all selected target genes, but not to the GAPDH promoter (Figure 
6B). For precipitation of PAX3-FOXO1 we used a PAX3/7 antibody 
that has been recently used in ChIP analysis, since expression of 
WT PAX3 is 1,000-fold lower and, as such, negligible in RH4 cells 
(19, 36). Next, we observed that CHD4 also is specifically bound to 
the same fragments of all target genes. Interestingly, prior deple-
tion of CHD4 using the stable shRNA cells caused a clear reduc-
tion of PAX3-FOXO1 binding on all target genes (Figure 6C), 
whereas addition of doxycycline had no effect on the binding of 
Figure 7. CHD4 inhibition causes 
tumor regression in mouse xeno-
grafts. In vivo treatment of NOD/
SCID mice engrafted with RH4 
cells containing stably integrated 
doxycycline-inducible shCHD4#1 or 
shscr expression vectors. Mice bear-
ing palpable tumors were treated 
i.p. for 2 days with either vehicle 
control or doxycycline at a dose of 
53.3 mg/kg. Additionally, they were 
fed with doxycycline-supplemented 
or control food. (A) Absolute tumor 
volumes of FP-RMS xenografts as 
measured by caliper. Vehicle-treat-
ed control groups consisted of 
6 mice, and doxycycline-treated 
groups consisted of 5 (shscr) and 
7 (shCHD4#1) mice. (B) CHD4 
mRNA expression level in indicated 
tumors of doxycycline- or vehicle 
control–treated mice analyzed by 
quantitative real-time PCR. Tumors 
were isolated at the end of treat-
ment (black; tumor set shown in A) 
or after 4 days of treatment (red; 
separate tumor set). Fold changes 
of mRNA expression are normal-
ized to the mean of CHD4 expres-
sion in shscr vehicle control–treated 
tumors. (C) Immunohistochemical 
staining of tumors with indicated 
antibodies. Tumors were isolated 4 
days after the start of treatment.
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Additionally, experimental evidence supports a role for CHD4 
specifically in FP-RMS cell survival, which is a core function of 
the fusion protein. Interestingly, when comparing gene signa-
tures after CHD4 depletion with the transcriptional profile regu-
lated directly by PAX3-FOXO1 (33, 46, 52), we identified around 
40% of target genes as being coregulated, suggesting that genes 
responsible for cell survival might be part of this new limited sub-
set signature. The exact contribution of the individual genes to 
cell survival remains to be determined, as it is not to be expected 
that they all act as drivers. However, it is important to emphasize 
that few of the well-characterized PAX3-FOXO1 target genes 
were identified in our gene set enrichment analysis (Supplemen-
tal Table 3). These included ALK, CDH3, and TFAP2B, of which 
only TFAP2B has been implicated in cell survival previously (19). 
Attempts to correlate expression of these genes individually with 
patient survival data using published expression profiling data 
sets have failed so far (data not shown). Nevertheless, our data 
suggest that other epigenetic regulators such as members of the 
SWI/SNF complex that were also identified in the MS analysis 
might be involved in modulating expression of the remaining sub-
set of PAX3-FOXO1 target genes.
Mechanistically, it is, at this stage, not possible to deter-
mine the exact composition of the complex at the different loca-
tions. Although we first confirmed individual interactions for 
CHD4, LSD1, HDAC1, and HDAC2 under standard conditions, it 
remained unclear whether they all bind to the fusion protein via 
direct protein-protein interaction. Hence, we carried out immuno-
precipitation experiments under conditions where potential resid-
ual DNA is digested. Indeed, this dramatically reduced the amount 
of coprecipitated PAX3-FOXO1, allowing us to conclude that they 
bind nearby to small DNA fragments, and unlikely via direct pro-
tein-protein interactions. Whether this also applies to the other 
chromatin complexes identified remains to be demonstrated.
Given the strong impact of CHD4 on PAX3-FOXO1 target gene 
activation, it might even be plausible that CHD4 acts in a NuRD 
complex–independent manner. This hypothesis is supported by the 
observation that depletion of several other NuRD subunits by si RNA 
(HDAC1, HDAC2, RBBP7, GATAD2A, MTA2) had only minor effects 
on target gene expression (data not shown). Interestingly, it has been 
suggested previously that CHD4 can function outside of the repres-
sive NuRD complex to activate transcription (53–56). Such onco-
genic properties of CHD4 in FP-RMS are in agreement with find-
ings in other tumors such as glioblastoma and colorectal cancer (57, 
58). On the other hand, CHD4 is frequently mutated in endome-
trial cancers and colorectal or gastric cancers with microsatellite 
instability (59, 60), suggesting that its oncogenic or tumor-suppres-
sive functions depend on the cellular context.
Finally, we demonstrate that CHD4 depletion induces 
regression of FP-RMS tumors in xenograft mouse models, but, 
importantly, had no effect on FN-RMS tumors. Altogether, this 
validates CHD4 inhibition as a potential targeted strategy to 
inhibit an essential coregulator of PAX3-FOXO1 activity. Never-
theless, at present we cannot exclude the possibility that addi-
tional mechanisms besides modulation of PAX3-FOXO1 target 
genes contribute to the growth-suppressive phenotype, given 
that CHD4 has been also implicated in DNA damage response 
and G1/S cell cycle progression (61–64).
Interestingly, tumors that recurred after 21 days of treatment 
(Figure 7A) showed recovery of CHD4 mRNA expression levels to 
nearly 100% and comparable to those in untreated controls (Fig-
ure 7B). Hence, it is likely that cells with insufficient CHD4 deple-
tion did finally outgrow.
To investigate whether CHD4 depletion also affects FN-RMS 
tumors, we measured RD cell tumor growth in vivo under doxy-
cycline addition. Interestingly, we observed only a slight growth 
retardation by doxycycline per se, but no tumor regression upon 
CHD4 depletion (Supplemental Figure 10). This was not due to 
generally lower CHD4 expression levels in FN-RMS, as both sub-
types have a similar expression pattern assessed on a human RMS 
tumor tissue microarray (Supplemental Figure 11). Taken togeth-
er, these data clearly demonstrate that the epigenetic regulator 
CHD4 plays an important role in FP-RMS tumor progression and 
survival, and identify CHD4 as novel potential treatment target 
for this pediatric sarcoma.
Discussion
Although PAX3-FOXO1 expression on its own might not be suf-
ficient for RMS development, it is the dominant oncogenic driv-
er and sole relevant genetic abnormality in a large fraction of 
tumors (27). Since direct pharmacological inhibition of transcrip-
tion factors is still elusive, blocking the activity of PAX3-FOXO1 
accessory proteins may therefore represent a viable alternative 
therapeutic strategy.
In the current study, we provide the first comprehensive anal-
ysis of the interactome of PAX3-FOXO1 directly purified from 
FP-RMS cells. A biochemical proteomic approach was used in a 
first step and then followed by a functional siRNA screen evalu-
ating expression levels of selected PAX3-FOXO1 target genes as 
readout (47). Interestingly, the final list of 9 putative accessory 
proteins revealed 6 protein subunits of chromatin remodeling 
complexes, suggesting that the fusion protein influences diverse 
epigenetic mechanisms. This is remarkably similar to the function 
of other fusion proteins in pediatric sarcomas, such as the Ewing 
sarcoma fusion EWS-FLI1, which is known to use divergent chro-
matin remodeling mechanisms to orchestrate target gene expres-
sion (48), and the SSX-SS18 fusion, which disrupts the BAF com-
plex in synovial sarcoma (49).
Most of the chromatin remodelers identified are subunits of 
the NuRD complex, namely CHD4, LSD1, and RBBP4. Further, 
we identified additional components of this complex in our initial 
proteomic screen, namely RBBP7, MTA2, GATAD2A, GATAD2B, 
HDAC1, and HDAC2, suggesting that PAX3-FOXO1 might 
indeed interact with the NuRD complex. It has been demon-
strated that this remodeling complex is also required for EWS-
FLI1–mediated transcriptional repression (50), and inhibition of 
LSD1 using small-molecule inhibitors impaired Ewing sarcoma 
cell viability (51). Hence, we next thought to identify components 
of the complex that might be necessary for PAX3-FOXO1 func-
tion. Whereas we observed only minor effects on proliferation of 
FP-RMS cells upon genetic depletion of LSD1, CHD4 depletion 
decreased FP-RMS cell proliferation and induced cell death to an 
extent similar to that seen with inhibition of PAX3-FOXO1 itself, 
without influencing proliferation of normal human fibroblasts 
and myoblasts, thereby opening a potential therapeutic window. 
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Coomassie (InstantBlue, Expedeon) or by silver staining (Bio-Rad). 
Coomassie-stained gels were cut into slices and prepared for MS as 
described in Supplemental Methods.
SiRNA screen. A siRNA library (Supplemental Table 2) targeting 
60 candidate interactors identified in the primary MS analysis (Ambi-
on Silencer Select Custom siRNA Library, Thermo Fisher Scientific, 
LuBioScience) was used with 3 unique siRNAs per target. Silencer 
Select Negative Control siRNA (4390846) served as nontargeting neg-
ative control and PAX3-FOXO1 breakpoint-specific siRNA (18) as pos-
itive control (both Ambion, Thermo Fisher Scientific, LuBioScience). 
For silencing of gene expression, 40,000 RH4 cells were reverse 
transfected with 4.6 nM siRNA in 24-well format using Interferin 
transfection reagent according to the manufacturer’s protocol (Poly-
plus Transfection SA). RNA was harvested 48 hours after transfection 
and used for quantitative real-time PCR.
Western blotting. For Western blots, total protein extracts were 
obtained from cells lysed with RIPA buffer containing 50 mM Tris-
Cl (pH 7.5), 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 1 mM 
EGTA, 0.1% SDS, 50 mM NaF, 10 mM sodium β-glycerolphosphate, 
5 mM sodium pyrophosphate, and 1 mM sodium orthovanadate and 
supplemented with Complete Mini Protease Inhibitor cocktail (Roche 
Diagnostics). Protein concentration was measured with Pierce BCA 
protein Assay Kit (Thermo Fisher Scientific, LuBioScience). Proteins 
were separated using 4%–12% Bis-Tris SDS-PAGE gels (Thermo Fish-
er Scientific, LuBioScience) and transferred to nitrocellulose mem-
branes (Protran, Schleicher & Schuell). After blocking with 5% milk 
powder in TBS/0.1% Tween, membranes were incubated with prima-
ry antibodies overnight at 4°C. After washing in TBS/0.1% Tween, 
membranes were incubated with HRP-linked IgG antibodies. Proteins 
were detected by chemiluminescence using ECL detection reagent or 
SuperSignal West Femto Maximum Sensitivity Substrate (both Ther-
mo Fisher Scientific) after washing in TBS/0.1% Tween.
Coimmunoprecipitation. Cells were lysed in 1 ml lysis buffer per 
10-cm dish and incubated for 1 hour at 4°C with antibody directed 
against the protein of interest coupled to Dynabeads Protein G (Novex 
by Thermo Fisher Scientific, LuBioScience) or empty beads as negative 
control. Antibodies used were directed against FOXO1 (C-20) (sc-9808, 
Santa Cruz Biotechnology), FLAG-tag (Sigma-Aldrich), or CHD4 (A301-
082A, polyclonal, rabbit, Bethyl Laboratories). Benzonase (Novagen) 
was added to the lysate during this incubation when indicated. After 
washing 4 times with lysis buffer, proteins were eluted with 200 μg/ml 
3X FLAG peptide or with 1X NuPAGE LDS sample buffer (Thermo Fish-
er Scientific, LuBioScience) at 70°C and analyzed by Western blotting.
Detection of DNA fragmentation by agarose gel electrophoresis. 
Twelve microliters of immunoprecipitation supernatants were run on 
1% agarose gels, and resolved DNA was stained with GelRed.
Cell viability assay. For cell viability assays, aRMS, MRC5, and human 
myoblast cells were cultured in 96-well format. At various time points 
after induction of shRNA expression, cell viability was measured by 
WST-1 assay (Roche Diagnostics) and normalized to uninduced control 
cells. At least 3 biological replicates were performed for each experiment.
Clonogenic assay. For clonogenic assays, 24 hours after induction 
of shRNA expression, 2,000 (RH4) or 5,500 (RMS) cells were seed-
ed on 6-well plates. Doxycycline-containing complete medium was 
changed every second to third day. After 12 days of incubation, cells 
were fixed with 4% formaldehyde solution and stained with 0.05% 
crystal violet, and colonies were counted.
To our knowledge our experiments identify the first chro-
matin remodeler contributing to PAX3-FOXO1 transcriptional 
regulation. Since CHD4 contains ATPase activity, it might be 
an amenable target to inhibit PAX3-FOXO1 activity indirect-
ly. However, the ATPase domain is highly conserved within the 
SNF2 family of helicase-like ATPases and therefore might be dif-
ficult to target specifically (65). Alternatively, CHD4 contains 2 
plant homeodomain (PHD) fingers and tandem chromodomains 
required for ATP-dependent chromatin remodeling, which could 
provide targets for drug design similar to the striking success in 
targeting BET bromodomains (66–70). Given the recognized role 
of the NuRD complex in other sarcomas, such as Ewing sarcoma, 
inhibition of CHD4 might be of therapeutic benefit for a broader 
range of tumors as well.
Methods
Cell lines. The aRMS cell lines RH4 (provided by Peter Houghton, Gree-
hey Children’s Cancer Research Institute, San Antonio, Texas, USA), 
RMS13 (provided by Roland Kappler, Ludwig–Maximilian University, 
Munich, Germany), and RMS (provided by Janet Shipley, The Institute 
of Cancer Research, London, United Kingdom), and MRC5 normal lung 
fibroblast cells, the eRMS cell line RD, and the HEK293T cell line for 
the production of lentiviral particles (all 3 purchased from the ATCC, 
LGC Promochem, Molsheim, France), were routinely maintained in 
DMEM (Sigma-Aldrich) supplemented with 10% FBS (Thermo Fisher 
Scientific, LuBioScience), 2 mM l-glutamine, and 100 U/ml penicillin/
streptomycin. The human myoblast cell line KM155C25Dist (provided 
by Vincent Mouly, Institut de Myologie, Paris, France) was maintained 
in Skeletal Muscle Cell Growth Medium Supplement Mix (PromoCell), 
15% FBS, 2 mM l-glutamine, and 100 U/ml penicillin/streptomycin. All 
cells were cultured in 5% CO2 at 37°C. All RMS and the MRC5 cell line 
were authenticated by short tandem repeat analysis (STR) profiling in 
2014/2015 and positively matched (71). As the human myoblast cell line 
has not yet been characterized by STR profiling, negative matching with 
all available cell lines in the database was used for verification.
Purification of FLAG-PAX3-FOXO1. RH4 and RMS13 cells were 
transfected with pCMV-N/C-FLAG-PAX3-FOXO1 or pBABE puro 
N-FLAG-PAX3-FOXO1 in 15-cm plates and lysed 48 hours after 
transfection with a mild lysis buffer containing 50 mM Tris-Cl (pH 
7.5), 125 mM NaCl, 10% glycerol, 0.3% NP-40, 1.5 mM MgCl2, 25 
mM NaF, 10 mM sodium β-glycerolphosphate, 5 mM sodium pyro-
phosphate, and 2 mM sodium orthovanadate and supplemented 
with Complete Mini Protease Inhibitor cocktail (Roche Diagnos-
tics). FLAG-PAX3-FOXO1 was immunoprecipitated using 100 μl 
Dynabeads Protein G (10004D, 30 mg/ml; Thermo Fisher Scien-
tific, LuBioScience) per plate coupled to 8 μg monoclonal ANTI-
FLAG M2 antibody (F1804, Sigma-Aldrich). After incubation for 10 
minutes at 4°C, beads were washed 3 times with lysis buffer, and 
bound FLAG-PAX3-FOXO1 was eluted with 40 μl elution buffer 
containing 200 μg/ml 3X FLAG peptide (F4799, Sigma-Aldrich), 
50 mM Tris-Cl (pH 7.4), and 150 mM NaCl. For each MS experi-
ment the eluates of 12 plates (RMS13) or 24 plates (RH4) were 
combined and concentrated using the Uppa-Protein Concentrate 
kit (786-120, GBiosciences, VWR International AG), according 
to the manufacturer’s instructions. After addition of 4X NuPAGE 
LDS buffer (Thermo Fisher Scientific, LuBioScience), proteins 
were separated by gel electrophoresis and stained with colloidal 
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Mayers HTX (catalog 01820, Histolab; 10 minutes) and Eosin aque-
ous (catalog 2C-140, Waldeck; 0.5%, 5 minutes). After staining, slides 
were dehydrated and mounted with Pertex. Immunohistochemistry 
was performed on Leica BondMax instruments using Refine HRP Kits 
(Leica DS9800) including all buffer solutions from Leica Microsys-
tems, processed according to the manufacturer’s guidelines. Antigen 
retrieval for Cleaved Caspase-3 (9661, Cell Signaling Technology; 
dilution 1:500) was performed with Epitope Retrieval buffer (Lei-
ca AR9640) at 100°C for 60 minutes. Slides for CHD4 ChIP Grade 
(ab70469, Abcam Ltd.; dilution 1:500) were pretreated with Epitope 
Retrieval buffer (Leica AR9961) at 100°C for 30 minutes.
Statistics. All statistical analysis (with the exception of microarray 
and GSEA analysis) was performed with GraphPad Prism software 
version 6. One-way ANOVA tests with Dunnett’s method for multi-
ple comparisons with a 95% CI were used to analyze data involving 
2 or more test groups and a control group. All statistical analysis of 
quantitative real-time PCR data was performed on the level of the 
ΔΔCt values. One-way ANOVA tests with uncorrected Fisher’s LSD 
method with a 95% CI were used for pairwise comparisons of several 
test groups. P values less than 0.05 were considered statistically sig-
nificant. Data are presented as the geometric mean with 95% CI or as 
mean ± SD unless otherwise noted.
Study approval. All animal experiments were approved by the 
Swiss veterinary authorities and were performed according to the ani-
mal license 208/2012.
Information regarding plasmids, transfection methods, lentiviral 
transduction, immunohistochemistry, tissue array, antibodies, quan-
titative real-time PCR, MS, and database searching including protein 
identification can be found in Supplemental Methods.
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Cell death and caspase-3/7 activity assays. Cells were seeded in 
white 384-well plates with clear bottom (Greiner Bio-One). Caspase 
activity was determined by Caspase-Glo 3/7 Assay (Promega) at 
indicated time points according to the manufacturer’s instruc-
tions. Luminescence was measured using the multidetection 
microplate reader Synergy HT (Bio-Tek Instruments). For analysis 
of caspase-3/7 activity in individual cells, they were stained with 
NucView 405 Caspase-3 Substrate (Biotium, Chemie Brunschwig 
AG) and analyzed by flow cytometry. For quantification of dead cells, 
NucView 405 Caspase-3 Substrate was combined with 7-AAD stain-
ing solution (BD Biosciences).
Microarray analysis. For gene expression profiling, RNA of RH4 cells 
was isolated from untreated cells, and 24, 48, and 72 hours after induction 
of CHD4 silencing (shCHD4#1) using RNeasy Kit (Qiagen), with DNase 
digestion step, according to the manufacturer’s instructions. Affymetrix 
GeneChip expression analysis was performed using HGU133plus2 arrays 
(Affymetrix Inc.). cRNA target synthesis and experimental procedures 
for GeneChip hybridization and scanning were carried out according to 
the “GeneChip eukaryotic small sample target labeling technical note” 
(Affymetrix, ATLAS Biolabs). Expression data were combined with pre-
vious published PAX3-FOXO1 gene expression data (19). The data sets 
are available for unrestricted download from Gene Expression Omnibus 
under the accession numbers GSE73480 and GSE73483. Batch normal-
ization and unsupervised hierarchical clustering were performed using 
dChip software. Gene set enrichment analysis (GSEA) was performed 
using GSEA version 2 software (Broad Institute) (72).
ChIP. ChIP has been recently described (73). For each ChIP assay, 
30 μg of cross-linked and sonicated chromatin was incubated with 
4 μg of antibody. Purified ChIP DNA was measured for enrichment 
of PAX3-FOXO1 binding sites by quantitative real-time PCR using 
TaqMan assays. Primer set and TaqMan probes are described in Sup-
plemental Table 5.
Xenograft studies. For the generation of xenograft, 5 × 106 RH4 
cells, containing stably integrated tetracycline-inducible shCHD4#1 or 
shscr expression construct, were transplanted s.c. into 8- to 12-week-
old female NOD/SCID mice (Charles River). After first detection of 
palpable tumors, mice were treated i.p. with either sterile PBS or doxy-
cycline solution at 53.3 mg/kg on 2 consecutive days. Doxycycline was 
diluted in PBS at a concentration of 8 mg/ml. Additionally, starting 
from the first day of treatment, mice were fed with doxycycline-supple-
mented food (625 mg doxycycline/kg) or control food. Tumor size was 
determined every day by measurement of 2 diameters (d1, d2) in right 
angles using a digital caliper. Total tumor volumes were calculated by 
the formula V = (4/3)πr3; r = (d1 + d2)/4. Control mice were euthanized 
when reaching a tumor volume of 1,700 mm3.
Immunohistochemistry. Tumor tissue was cut into slices of 4–5 
mm and fixed in 4% vol/vol neutralized formalin for 24 hours at room 
temperature, processed in a Pathos Delta (Milestone) overnight with 
ethanol and isopropanol for dehydration and paraffin embedding. 
Samples were molded in paraffin blocks and sectioned on a Leica 
rotary microtome into 3-μm-thick slices. After drying at 64°C for 30 
minutes, slides were stained with H&E in a Leica Autostainer using 
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